Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Felbamate
Drug ID BADD_D00871
Description Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Indications and Usage For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
Marketing Status Prescription
ATC Code N03AX10
DrugBank ID DB00949
KEGG ID D00536
MeSH ID D000078328
PubChem ID 3331
TTD Drug ID D05KON
NDC Product Code 51525-0442; 51672-4185; 63629-1944; 0037-0431; 62559-731; 17381-554; 0037-0430; 65162-734; 43826-255; 47621-054; 42385-721; 51672-4172; 69988-0032; 51672-4186; 72578-056; 66689-825; 51525-0430; 46016-2542; 62559-730; 16714-775; 73223-003; 47781-630; 47781-627; 70771-1077; 63629-1937; 43826-256; 0121-0891; 72578-057; 65162-686; 0037-0442; 70771-1078; 51525-0431; 65162-735; 22365-007
Synonyms Felbamate | 2-Phenyl-1,3-propanediol dicarbamate | 2 Phenyl 1,3 propanediol dicarbamate | Taloxa | Felbatol | Felbamyl | ADD-03055 | ADD 03055 | ADD03055 | (3-Carbamoyloxy-2-phenyl-propyl) carbamate | W-554 | W 554 | W554
Chemical Information
Molecular Formula C11H14N2O4
CAS Registry Number 25451-15-4
SMILES C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acne23.02.01.001--Not Available
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Aggression19.05.01.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Anencephaly03.10.03.001; 17.19.03.001--Not Available
Anxiety19.06.02.002--
Apathy19.04.04.002--Not Available
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia supraventricular02.03.03.001--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Ataxia08.01.02.004; 17.02.02.001--
Atrial fibrillation02.03.03.002--
Blood lactate dehydrogenase increased13.04.02.002--
Body temperature decreased13.15.01.010--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cerebrovascular disorder17.08.02.002; 24.03.05.002--Not Available
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene